The Oil Drilling Rig Industry is characterized with a few typical work specific to this industry only. The work begins with the search for new oil basins or construction of wells. During this time the services of drilling contractors and se…
Examine the future of biologics in the Polish pharma market.
Report surveys biologic and biosimilar drugs, epidemiology and growth potential 2013- 2015.
In Poland, as in many parts of the world, a growing number of patients are being treated using biological or biosimilar drugs. The list of illnesses for which these drugs are prescribed includes psoriasis, Crohn's disease, colitis, psoriatic and rheumatoid arthritis, ankylosing spondylitis and others. Consequently, the market has expanded recently to encompass new drugs and therapies designed to treat a growing variety of conditions and illnesses.
Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 is a new PMR report designed to evaluate current market conditions and investigate the possibilities for growth and expansion in the coming years. From market size to research and development efforts of leading companies, this publication offers expert analysis of this market.
This document analyses the epidemiology fueling the growth of biologics in Poland, revealing the number of patients receiving these drugs. It analyses the reasons behind expansion and the potential obstacles that exist or will appear by 2015.
The competitive atmosphere of this segment of Poland's pharmaceuticals market is carefully evaluated using profiles of the major Polish manufacturing companies active in this market that include financial condition updates, plans for upcoming additions to their product lines and plans to engage in new research and development activities. Recent entries into the Polish biologics market are examined along with the likelihood of M&A and consolidation activity in the next two years.
The expiration of various patents for biologic drugs is a timely market topic, and this publication highlights the businesses ready to capitalise on new developments. It reviews the mechanics of the market, offering explanation of the registration and refund procedures that apply to biologics in Poland and covering recent and upcoming regulatory changes and their likely impact on businesses supplying this market.
Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 is a long-awaited business information tool that will aid companies involved in the manufacturing and distribution of these drugs within the Polish market and especially those which want to enter this young market. Related companies engaged in ingredient manufacturing and drug research will also find this report vital to new drug development, keeping up with legal requirements for business operation in this segment and preparing corporate reports and forecasts for internal use. Users of this publication come from pharmaceutical companies, consulting and research services providers and government agencies, financial institutions and chambers of commerce.